Immune checkpoint inhibitor‐related cutaneous adverse events-Reference-Cited by-同舟云学术

Immune checkpoint inhibitor‐related cutaneous adverse events

Published:2020-08-12 Issue:5 Volume:16 Page:
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

He Chunxia¹,Qu Tao¹

Affiliation:

1. Department of Dermatology National Clinical Research Center for Skin and Immune Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing China

Funder

CAMS Innovation Fund for Medical Sciences

CAPTRA Immunotherapy and Immune-Related Adverse Events management platform

“13th Five-Year” National Science and Technology Major Project for New Drugs

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13364

Reference28 articles.

1. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

3. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

4. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System

5. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma;British Journal of Dermatology;2024-02-29

2. A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors;Italian Journal of Dermatology and Venereology;2023-11

3. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach;British Journal of Dermatology;2023-10

4. Tumor-responsive dynamic nanoassemblies for boosted photoimmunotherapy;Nano Research;2023-07-24

5. Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies;Clinical and Experimental Dermatology;2022-11-01